Higher Eye Pressure After Anti-VEGF Therapy Needs More Attention

Source: Reuters

The elevated IOP known to follow intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents may persist in certain patients, according to a report by the American Academy of Ophthalmology (AAO), as reported by Reuters.

“While more studies are needed to identify which patients are at risk, physicians should be aware of this phenomenon and begin appropriate monitoring and treatment for glaucoma in patients whose IOP does not normalize in a reasonable time-frame,” Dr. Ambika Hoguet of Ophthalmic Consultants of Boston told Reuters Health by email.

In the new report, online November 22 in Ophthalmology, Dr. Hoguet and colleagues reviewed data from 34 studies covering patients with a mean age between 61 and 85 years.

Read the full article.

Related Content